Brokerages Expect Edwards Lifesciences Corp (EW) Will Announce Earnings of $1.23 Per Share

Wall Street brokerages expect that Edwards Lifesciences Corp (NYSE:EW) will announce $1.23 earnings per share for the current fiscal quarter, Zacks Investment Research reports. Eight analysts have issued estimates for Edwards Lifesciences’ earnings. The lowest EPS estimate is $1.20 and the highest is $1.31. Edwards Lifesciences posted earnings per share of $1.22 during the same quarter last year, which would indicate a positive year over year growth rate of 0.8%. The company is scheduled to announce its next earnings report after the market closes on Tuesday, April 23rd.

According to Zacks, analysts expect that Edwards Lifesciences will report full year earnings of $5.22 per share for the current year, with EPS estimates ranging from $5.15 to $5.28. For the next financial year, analysts anticipate that the business will report earnings of $5.81 per share, with EPS estimates ranging from $5.10 to $6.05. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research analysts that follow Edwards Lifesciences.

Edwards Lifesciences (NYSE:EW) last announced its earnings results on Thursday, January 31st. The medical research company reported $1.17 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $1.17. The business had revenue of $977.70 million for the quarter, compared to analyst estimates of $973.72 million. Edwards Lifesciences had a net margin of 19.40% and a return on equity of 31.09%. During the same period last year, the firm posted $0.94 earnings per share.

Several brokerages recently weighed in on EW. Credit Suisse Group increased their price target on Edwards Lifesciences from $189.00 to $221.00 and gave the stock an “outperform” rating in a report on Monday. JPMorgan Chase & Co. increased their price target on Edwards Lifesciences from $175.00 to $190.00 and gave the stock a “neutral” rating in a report on Wednesday, March 27th. They noted that the move was a valuation call. Barclays increased their price target on Edwards Lifesciences from $150.00 to $160.00 and gave the stock an “underweight” rating in a report on Monday, March 25th. BMO Capital Markets raised their target price on Edwards Lifesciences to $204.00 and gave the company an “outperform” rating in a report on Friday, March 22nd. Finally, Morgan Stanley raised their target price on Edwards Lifesciences from $180.00 to $197.00 and gave the company an “overweight” rating in a report on Monday, March 18th. Two research analysts have rated the stock with a sell rating, seven have given a hold rating and thirteen have issued a buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $182.29.

Shares of EW traded down $0.23 during mid-day trading on Thursday, reaching $177.26. 2,633,765 shares of the company’s stock were exchanged, compared to its average volume of 1,323,478. The company has a current ratio of 2.61, a quick ratio of 1.92 and a debt-to-equity ratio of 0.19. The firm has a market cap of $39.61 billion, a PE ratio of 37.71, a price-to-earnings-growth ratio of 2.46 and a beta of 0.91. Edwards Lifesciences has a 52-week low of $123.00 and a 52-week high of $197.86.

In other Edwards Lifesciences news, VP Catherine M. Szyman sold 1,474 shares of the firm’s stock in a transaction on Monday, April 15th. The stock was sold at an average price of $192.00, for a total value of $283,008.00. Following the completion of the sale, the vice president now owns 21,132 shares of the company’s stock, valued at $4,057,344. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, VP Larry L. Wood sold 6,716 shares of Edwards Lifesciences stock in a transaction on Monday, April 1st. The stock was sold at an average price of $192.34, for a total value of $1,291,755.44. Following the transaction, the vice president now directly owns 122,495 shares of the company’s stock, valued at approximately $23,560,688.30. The disclosure for this sale can be found here. In the last three months, insiders sold 114,328 shares of company stock valued at $20,121,304. 1.63% of the stock is owned by corporate insiders.

Several large investors have recently added to or reduced their stakes in the company. Capital Insight Partners LLC raised its stake in shares of Edwards Lifesciences by 0.5% during the 1st quarter. Capital Insight Partners LLC now owns 11,010 shares of the medical research company’s stock worth $2,107,000 after buying an additional 53 shares during the last quarter. Cetera Advisor Networks LLC increased its position in Edwards Lifesciences by 3.8% during the 4th quarter. Cetera Advisor Networks LLC now owns 1,573 shares of the medical research company’s stock worth $242,000 after purchasing an additional 57 shares in the last quarter. Kentucky Retirement Systems increased its position in Edwards Lifesciences by 0.7% during the 4th quarter. Kentucky Retirement Systems now owns 9,093 shares of the medical research company’s stock worth $1,393,000 after purchasing an additional 60 shares in the last quarter. Parallel Advisors LLC increased its position in Edwards Lifesciences by 11.2% during the 4th quarter. Parallel Advisors LLC now owns 684 shares of the medical research company’s stock worth $101,000 after purchasing an additional 69 shares in the last quarter. Finally, BB&T Securities LLC increased its position in Edwards Lifesciences by 0.9% during the 4th quarter. BB&T Securities LLC now owns 8,179 shares of the medical research company’s stock worth $1,252,000 after purchasing an additional 70 shares in the last quarter. 84.88% of the stock is owned by institutional investors and hedge funds.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic valve replacement, and transcatheter mitral and tricuspid therapies for the nonsurgical replacement of heart valves.

See Also: Quiet Period

Get a free copy of the Zacks research report on Edwards Lifesciences (EW)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.